Saxagliptin hydrate Catalog No.:M8618-2 Umifenovir inhibits membrane fusion

Umifenovir inhibits membrane fusion

GSK429286A at 1 μM reduces ROCK2 activity over 20-fold

RA-9 is a cell-permeable

InChi: InChI=1S/C17H15NO2/c1-2-20-16-10-6-3-7-12(16)11-14-13-8-4-5-9-15(13)18-17(14)19/h3-11H

552309-42-9

Saxagliptin hydrate Catalog No.:M8618-2 Umifenovir inhibits membrane fusionSaxagliptin, also known as BMS 477118, is a new oral hypoglycemic (anti diabetic drug) of the new dipeptidyl peptidase 4 (DPP 4) inhibitor class of drugs. Saxagliptin was approved in 2008 for the treatment of type 2 diabetes. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose